RNAC
Cartesian Therapeutics Inc.
7.40$
+1.9%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +92.7% | +108.5% | +13.2% | -56.0% | +123.8% | +66.2% | -3.4% | +3.8% | +83.9% | +42.6% | -31.9% | |
| – | +103.6% | +123.1% | +13.7% | -57.4% | +129.7% | +56.6% | -4.6% | +2.6% | -38.8% | +138.8% | -40.3% | |
| – | +94.9% | +81.4% | +20.5% | -47.1% | +141.1% | +53.8% | -17.8% | -6.7% | -27.7% | +176.4% | -41.1% | |
| – | +119.8% | +130.8% | +14.9% | -61.3% | +141.1% | +53.8% | -7.7% | +5.1% | -42.9% | +176.4% | -41.1% | |
| – | +22.3% | -73.9% | -70.7% | – | – | +44.5% | +37.2% | -0.6% | -10.2% | -90.1% | +27.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +2.3% | +0.9% | +2.1% | +1.7% | -28.4% | -8.4% | +53.5% | +30.4% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | +0.0% | +0.0% | |
| – | – | – | – | – | – | – | – | – | – | +0.0% | -37.6% | |
| – | +44.9% | -78.4% | +43.5% | +1.2% | +82.7% | +101.2% | -25.1% | -47.5% | +934.2% | -40.7% | -4.3% | |
| – | -21.0% | +88.0% | -19.9% | +220.3% | -0.6% | +133.4% | -11.4% | -65.3% | +172.0% | -66.3% | -35.0% | |
| – | +31.0% | +20.4% | -100.0% | – | -9.9% | -95.3% | +672.0% | +43.9% | -78.5% | +31.6% | +45.6% | |
| – | +520.8% | +78.2% | -58.6% | -31.5% | -54.5% | -11.4% | -49.4% | +41.1% | +896.8% | -90.9% | +347.2% | |
| – | +145.8% | -32.7% | +163.8% | -100.0% | – | – | -20.7% | -9.6% | – | – | – | |
| – | – | – | -5.7% | -110.5% | – | -314.4% | – | +316.6% | -569.1% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +3,500.0% | -97.7% | +94.6% | +9.6% | +103.4% | +122.2% | +13.0% | +27.6% | +27.6% | +358.2% | +9.6% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.